Is SNY a good stock to buy?
We came across a bullish thesis on Sanofi on r/ValueInvesting by stefanliemawan
In this article, we will summarize the bulls’ thesis on SNY. Sanofi’s share was trading at $42.38 as of June 18th. SNY’s trailing and forward P/E were 18.43 and 8.44 respectively according to Yahoo Finance.
Photo by christina victoria on Unsplash Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. SNY is presented as a compelling combination of a defensive pharmaceutical company and a potential turnaround opportunity, with the market continuing to discount the business despite its strong portfolio, growing dividend, and ownership of one of the world’s most successful drugs. The company generated €47 billion in revenue last year, including approximately €19 billion from Dupixent, the blockbuster therapy it co-developed with Regeneron. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential Investor concerns are largely centered on Dupixent’s loss of U.S. exclusivity in March 2031, creating fears of a future patent cliff and contributing to Sanofi’s modest valuation of roughly 9x forward earnings.